Rosiglitazone

Chemical formula: C₁₈H₁₉N₃O₃S  Molecular mass: 357.427 g/mol  PubChem compound: 77999

Therapeutic indications

Rosiglitazone is indicated for:

Diabetes mellitus type 2

Population group: only adults (18 years old or older)

Rosiglitazone is indicated in the treatment of type 2 diabetes mellitus:

as monotherapy:

  • in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance

as dual oral therapy in combination with:

  • metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin
  • a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite monotherapy with a sulphonylurea

as triple oral therapy in combination with:

  • metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Rosiglitazone is contraindicated in the following cases:

Heart failure Class III or IV New York Heart Association (NYHA)

at least one of
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV
H/O: heart failure

Lactation

Lactation

Acute coronary syndrome

Acute coronary syndrome

Hepatic impairment

at least one of
Hepatic insufficiency
Elevated liver enzymes level

Diabetic ketoacidosis, diabetic pre-coma

at least one of
Diabetic ketoacidosis
Coma due to diabetes mellitus

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) : AVANDIA Film-coated tablet
Structured Product Labeling (SPL/PLR) 2020: AVANDIA Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈